



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|------------------------|--------------------------|--------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | Divisional of 10/028,547 |
| | | 10/623378 | |
| | | Filing Date | July 18, 2003 |
| | | First Named Inventor | Jay D. Kranzler |
| Group Art Unit | | | |
| Examiner Name | | | |
| Sheet 1 of 4 | Attorney Docket Number | CYPR 100 CIP DIV | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--------------------|-----------------------------------|---|-----------------------------------|
| Examiner Initials* | Cite No. ¹ | US Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| n | | 5,621,142 | | Machizuki | 04-15-1997 |
| n | | 4,478,836 | | Mouzin | 10-23-1984 |
| n | | 5,034,541 | | Bigg | 07-23-1991 |
| n | | 6,395,788 | | Iglehart, III | 05-28-2002 |
| n | | 6,441,038 | | Loder, et al. | 08-27-2002 |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | |
| | | EP | *0 759 299 | | Elit Lilly & Co. | 02-26-1997 |
| | | FR | *2 752 732 | | Pierre Fabre Medicament | 03-06-1998 |
| n | | WO | 95/22521 | | Asahi Kasei Kabushiki Kaisha | 08-24-1995 |
| n | | WO | 97/35574 | | Pierre Fabre Medicament | 10-02-1997 |
| | | WO | *WO 97/35584 | | Elit Lilly & Co. | 10-02-1997 |
| n | | WO | 98/08495 | | Pierre Fabre Medicament | 03-05-1998 |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|--------------------|-----------------|-----------------|---------|
| Examinee Signature | <i>N. Looch</i> | Date Considered | 2/27/04 |
|--------------------|-----------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation: number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|------------------------|--------------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | Divisional of 10/028,547 |
| | | | | Filing Date | July 18, 2003 |
| | | | | First Named Inventor | Jay D. Kranzler |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| Sheet | 2 | of | 4 | Attorney Docket Number | CYPR 100 CIP DIV |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|---|----|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T* |
| | | Office. ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| W | | PCT | WO 98/36744 | | Pierre Fabre Medicament | 08-27-1998 | | |
| | | PCT | *WO 99/59593 | | Eli Lilly & Co. | 11-25-1999 | | |
| | | PCT | *WO 00/32178 | | Mueller | 06-08-2000 | | |
| W | | PCT | WO 01/26623 | | Laxdale Ltd | 04-19-2001 | | |
| | | PCT | *WO 02/053140 | | Pharmacia & Upjohn Co. | 07-11-2002 | | |

| | | | |
|----------------------|-----------------|--------------------|---------|
| Examine Signature | <i>R. L. L.</i> | Date Considered | 9/27/04 |
|----------------------|-----------------|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----------------------|--------------------------|------------------------|------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | Divisional of 10/028,547 | | |
| | | Filing Date | July 18, 2003 | | |
| | | First Named Inventor | Jay D. Kranzler | | |
| | | Group Art Unit | | | |
| | | Examiner Name | | | |
| Sheet | 3 | of | 4 | Attorney Docket Number | CYPR 100 CIP DIV |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| h | | ARDID, et al., "Antidepressants and pain," La Lettre de Pharmacologue 13: 8 (1993). | |
| h | | Cypress Bioscience, Inc., Investor Fact Sheet, August 2001. | |
| h | | DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000). | |
| | | DWIGHT, et al., "An open clinical trial of venlafaxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). | |
| | | GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin. Psychiatry 13-20 (1999). | |
| | | MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine..." PCT Int'l Appl. 14 (09/28/2000). | |
| h | | NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a case report," Med. Drug. J. 37: 10 (2001). | |
| | | NINAN, "Use of venlafaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). | |
| h | | NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and their protective effect against NMDA-induced neurotoxicity," Synapse 31: 87-96 (1999). | |
| | | NUTT & JOHNSON, "Potential applications of venlafaxine," Rev. Contemp. Pharmacother. 9: 321-331 (1998). | |

| | | | |
|----------------------|--------------|-----------------|---------|
| Examiner's Signature | <i>Reesh</i> | Date Considered | 9/27/04 |
|----------------------|--------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|----------------------|--------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | Divisional of 10/028,547 |
| | | Filing Date | July 18, 2003 |
| | | First Named Inventor | Jay D. Kranzler |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 4 of 4 | Attorney Docket Number | CYPR 100 CIP DIV | |

| OTHER ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | | *RAO, "The neuropharmacology of centrally-acting analgesic medications in fibromyalgia," Rheum. Dis. Clin. N. Amer. 28: 235-259 (2002). | |
| bx | | SHUTO, et al., "(+)-2-(Aminomethyl)-1-phenylcyclopropanecarboximide derivatives as a new prototype of NMDA receptor antagonists," J. Med. Chem. 38: 2964-2968 (1995). | |
| n | | SHUTO, et al., "(1S,2R)-1-(phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy," Jpn. J. Pharmacol. 85: 207-213 (2001). | |
| u | | SHUTO, et al., "Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-(phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist," J. Med. Chem. 39: 4844-4852 (1996). | |
| a | | SHUTO, et al., "Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S,2R)-1-phenyl-2-[(r)-1-amino-2-propynyl]-N,N-diethylcyclopropane-carboximide is a novel class of NMDA receptor channel blocker," J. Med. Chem. 41: 3507-3514 (1998). | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|----------------------|----------------|-----------------|---------|
| Examiner's Signature | <i>K. Woon</i> | Date Considered | 8/22/04 |
|----------------------|----------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.